<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663442</url>
  </required_header>
  <id_info>
    <org_study_id>K24-MHO1823</org_study_id>
    <nct_id>NCT00663442</nct_id>
  </id_info>
  <brief_title>Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>Dose Response Pharmacogenetic Study of ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA
      extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial
      with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS
      methylphenidate and placebo. Each week, parent report measures, clinical interviews, and
      safety assessments are conducted.

      Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype
      will predict response
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD RS</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VItal Signs</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Questionnaire</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects rating Scale</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROS methylphenidate</intervention_name>
    <description>18, 36, 54 mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6-17 DSM IV criteria for ADHD Parents willing to complete measures

        Exclusion Criteria:

          -  Mental retardation psychoses seizure disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Stein, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HALP Clinic, University of Illinois at CHicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003 Nov;112(5):e404.</citation>
    <PMID>14595084</PMID>
  </results_reference>
  <results_reference>
    <citation>Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, Conlon C, Kim SJ, Cook EH. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005 Jul;30(7):1374-82.</citation>
    <PMID>15827573</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Stein Ph.D.</name_title>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>side effects</keyword>
  <keyword>sleep</keyword>
  <keyword>dopamine</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

